0001179110-21-000648.txt : 20210115 0001179110-21-000648.hdr.sgml : 20210115 20210115160456 ACCESSION NUMBER: 0001179110-21-000648 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210113 FILED AS OF DATE: 20210115 DATE AS OF CHANGE: 20210115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Utter Christine Marie CENTRAL INDEX KEY: 0001707685 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 21532130 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 edgar.xml FORM 4 - X0306 4 2021-01-13 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001707685 Utter Christine Marie C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 SVP, Finance & CAO Common Stock 2021-01-13 4 S 0 659 66.57 D 17529 D Common Stock 2021-01-13 4 M 0 788 11.23 A 18317 D Common Stock 2021-01-13 4 S 0 788 66.57 D 17529 D Common Stock 2021-01-13 4 M 0 2500 18.01 A 20029 D Common Stock 2021-01-13 4 S 0 2500 66.57 D 17529 D Stock Option (Right To Buy) 11.23 2021-01-13 4 M 0 788 11.23 D 2027-01-02 Common Stock 788.0 0 D Stock Option (Right to Buy) 18.01 2021-01-13 4 M 0 2500 18.01 D 2028-01-02 Common Stock 2500 10000 D Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 74.0 74 D Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 21.0 21 D Stock Option (Right To Buy) 40.45 2024-09-23 Common Stock 4688.0 4688 D Stock Option (Right To Buy) 51.0 2025-01-02 Common Stock 17800.0 17800 D Stock Option (Right to Buy) 33.02 2029-01-21 Common Stock 23907 23907 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 10100.0 10100 D Stock Option (Right To Buy) 51.16 2030-01-28 Common Stock 23800.0 23800 D Stock Option (Right to Buy) 66.49 2031-01-05 Common Stock 50750 50750 D This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2020. Currently exercisable. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. /s/ Avraham S. Adler, attorney-in-fact 2021-01-15